Avila Therapeutics™
Covalent Drugs: Bonding to Targets, Silencing the Disease

Avila Therapeutics will treat human diseases using a remarkably powerful therapeutic approach called ‘protein silencing.’ Using our Avilomics™ platform, we generate covalent drugs that strongly and resiliently bond to specific disease-causing proteins, thereby “silencing” them and eradicating the corresponding disease. Avila’s novel covalent drugs have the potential to improve patient outcomes in a fundamentally new way, and Avila is rapidly developing these therapies for a number of diseases, including viral infections, cancers and autoimmune diseases.

6/28/10
Avila Therapeutics Presents New Btk Inhibitor Data at Federation of Clinical Immunology Societies Meeting, FOCIS 2010

6/25/10
Avila Therapeutics Presents New AVL-192 Data at the 5th International Workshop on Hepatitis C: Resistance and New Compounds

6/17/10
Avila Therapeutics Presents at the Gordon Bioorganic Chemistry Conference

5/25/10
Clovis Oncology and Avila Therapeutics Sign $209 Million Partnership for the Worldwide Development and Commercialization of EGFR Mutant-Selective Inhibitor

4/16/10
Avila Presents Preclinical Data on two Novel, Orally-Available Protease Inhibitors, AVL-181 and AVL-192, for Hepatitis C Infection at EASL 2010 Meeting

03/29/10
Avila establishes $3.2M collaboration with Leukemia & Lymphoma Society

03/10/10
Avila Presents at Cowen and Company 30th Annual Health Care Conference

01/28/10
Bio-IT World.com "Avila Therapeutics targets the covalent proteome."

11/02/09
Avila Presents Preclinical Data on its Novel, Orally-Available Protease Inhibitor, AVL-181, Demonstrating Viral Clearance of Hepatitis C Virus in Preclinical Models

10/5/09
Avila Presents Preclinical Data on its Novel, Orally-Available, Pan-Genotype Protease Inhibitor, AVL-181, Demonstrating Protein Silencing of Hepatitis C Virus

9/25/09
EP Vantage: Avila covalent drugs looking highly attractive

7/28/09
BioWorld: Avila Raises $30M, Pulls Down $200M Deal with Novartis Fund

7/27/09
Avila Therapeutics, Inc. Closes $30 Million Series B Financing

7/27/09
Avila Therapeutics Announces Agreement with Novartis to Develop Novel Covalent Drug Candidate

5/15/09
Avila Therapeutics Appoints Katrine S. Bosley as Company’s First CEO

4/25/09
Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting

4/21/09
Avila Presents Data on Novel, Orally-Available, Covalent Drugs Targeting Btk and ErbB Receptors, and Innovative Translation Technology, at Annual AACR Meeting